Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE versus DRISDOL.
Head-to-head clinical analysis: CALCIPOTRIENE versus DRISDOL.
CALCIPOTRIENE vs DRISDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
None Documented
None Documented
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Category C
Category C
Vitamin D Analog
Vitamin D Analog